Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.57.

A number of analysts have recently issued reports on NMRA shares. Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Weiss Ratings upgraded shares of Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. Finally, Royal Bank Of Canada lowered their target price on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th.

Insider Buying and Selling

In other news, insider Daljit Singh Aurora sold 91,690 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.50, for a total value of $137,535.00. Following the transaction, the insider owned 48,750 shares of the company’s stock, valued at $73,125. This represents a 65.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 453,833 shares of company stock valued at $701,219. 26.94% of the stock is owned by insiders.

Institutional Trading of Neumora Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at about $13,246,000. Perceptive Advisors LLC bought a new position in Neumora Therapeutics during the 1st quarter worth approximately $9,953,000. ICONIQ Capital LLC bought a new position in Neumora Therapeutics during the 2nd quarter worth approximately $4,350,000. Siren L.L.C. increased its stake in Neumora Therapeutics by 35.1% in the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock worth $16,571,000 after purchasing an additional 2,209,039 shares during the period. Finally, Johnson & Johnson purchased a new position in Neumora Therapeutics in the 2nd quarter worth approximately $3,144,057. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $0.50 on Friday. The firm has a market capitalization of $94.57 million, a price-to-earnings ratio of -0.41 and a beta of 3.12. Neumora Therapeutics has a 52-week low of $0.32 and a 52-week high of $3.65. The stock has a fifty day moving average of $0.69 and a 200 day moving average of $1.74. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Friday, August 14th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. On average, research analysts expect that Neumora Therapeutics will post -0.84 EPS for the current fiscal year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora’s pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure.